AZTA

Azenta is a life-sciences sample-management and multiomics provider that has been actively reshaping its portfolio since selling the semiconductor automation business for $2.9B in 2022. FY2025 revenue grew just 3.6% to $594M, gross margin held at a respectable 45.5%, and the operating loss narrowed from a deeper hole to -$26.8M (-4.5% margin). The net loss of $55.8M (-9.4% margin) is a 66% improvement YoY, but the business is still unprofitable three years after the semi-cap divestiture, with ROE at -3.3%. The MD&A discloses that in preparing FY2025 statements, management identified errors in previously issued financials and revised FY2023-2025 — concluded immaterial, but it is the kind of disclosure that demands a discount until trust rebuilds, and Risk Factors explicitly flags 'material weaknesses in internal control over financial reporting' as a live concern.

The balance sheet is the saving grace and the reason this is not an 'avoid': $280M cash, only $339M total liabilities against $1.70B equity (0.20x leverage), and FY2025 operating cash flow of $72.2M against $33.9M capex — roughly $38M of free cash flow despite GAAP losses, helped by $61.2M of D&A. The pending sale of B Medical Systems (classified as held-for-sale, discontinued ops) should further simplify the story around core Sample Management Solutions and Multiomics. At $24.72 the market cap is $1.14B, or 1.9x sales — undemanding for a 45%-gross-margin life-sciences franchise, but appropriate given no GAAP profits, no buybacks in FY2025 (down from prior), and revenue stuck in a $510-595M band for five years.